Par Drugs & Chemicals Ltd
Incorporated in 1982, Par Drugs & Chemicals Ltd manufactures APIs and Fine Chemicals[1]
- Market Cap ₹ 346 Cr.
- Current Price ₹ 281
- High / Low ₹ 325 / 162
- Stock P/E 24.3
- Book Value ₹ 63.9
- Dividend Yield 0.00 %
- ROCE 23.0 %
- ROE 17.1 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 49.6% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
15 | 19 | 27 | 33 | 33 | 49 | 42 | 46 | 56 | 61 | 75 | 96 | 97 | |
14 | 15 | 20 | 26 | 26 | 40 | 34 | 38 | 46 | 45 | 59 | 78 | 75 | |
Operating Profit | 1 | 3 | 7 | 7 | 7 | 8 | 8 | 8 | 9 | 16 | 16 | 18 | 22 |
OPM % | 9% | 18% | 27% | 22% | 22% | 17% | 19% | 18% | 17% | 26% | 22% | 19% | 23% |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | |
Interest | 0 | 1 | 4 | 4 | 4 | 2 | 2 | 2 | 1 | 1 | 0 | 0 | 0 |
Depreciation | 0 | 1 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Profit before tax | 1 | 2 | 1 | 1 | 1 | 3 | 3 | 3 | 6 | 15 | 13 | 15 | 19 |
Tax % | 2% | 34% | 40% | 27% | 58% | 42% | 42% | 24% | 21% | 21% | 27% | 25% | |
1 | 1 | 1 | 1 | 0 | 2 | 2 | 3 | 5 | 12 | 9 | 11 | 14 | |
EPS in Rs | 4.74 | 2.07 | 1.33 | 1.65 | 0.78 | 3.43 | 2.78 | 2.79 | 3.87 | 9.44 | 7.49 | 9.21 | 11.56 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 32% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 18% |
3 Years: | 20% |
TTM: | 4% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 50% |
3 Years: | 33% |
TTM: | 38% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 69% |
1 Year: | 71% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 17% |
3 Years: | 18% |
Last Year: | 17% |
Balance Sheet
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 1 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 6 | 6 | 12 | 12 | 12 |
Reserves | 5 | 6 | 8 | 9 | 9 | 11 | 12 | 25 | 34 | 46 | 48 | 59 | 66 |
Preference Capital | 0 | 6 | 6 | 6 | 6 | 6 | 6 | 0 | 0 | 0 | 0 | 0 | |
12 | 10 | 38 | 33 | 31 | 25 | 23 | 12 | 6 | 8 | 0 | 0 | 0 | |
3 | 10 | 13 | 15 | 16 | 18 | 16 | 11 | 13 | 16 | 19 | 18 | 17 | |
Total Liabilities | 21 | 29 | 61 | 59 | 58 | 56 | 54 | 51 | 60 | 76 | 79 | 89 | 96 |
13 | 14 | 47 | 45 | 43 | 42 | 39 | 36 | 34 | 30 | 34 | 38 | 40 | |
CWIP | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 0 | 0 | 1 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
8 | 9 | 14 | 13 | 15 | 14 | 15 | 15 | 25 | 42 | 44 | 50 | 55 | |
Total Assets | 21 | 29 | 61 | 59 | 58 | 56 | 54 | 51 | 60 | 76 | 79 | 89 | 96 |
Cash Flows
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 1 | 5 | 9 | 7 | 9 | 4 | 2 | 8 | 12 | 8 | 13 | |
0 | -7 | -6 | -0 | -0 | -2 | -1 | -0 | -1 | 0 | -3 | -7 | |
0 | 6 | 2 | -9 | -5 | -8 | -4 | -2 | 1 | 2 | -10 | 0 | |
Net Cash Flow | 0 | 0 | 1 | -1 | 1 | -1 | 0 | -0 | 7 | 14 | -5 | 6 |
Ratios
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 72 | 67 | 104 | 83 | 81 | 61 | 75 | 67 | 81 | 75 | 90 | 65 |
Inventory Days | 129 | 111 | 158 | 69 | 83 | 81 | 45 | 50 | 60 | 49 | ||
Days Payable | 171 | 184 | 183 | 135 | 107 | 94 | 96 | 112 | 135 | 73 | ||
Cash Conversion Cycle | 72 | 67 | 62 | 10 | 57 | -5 | 51 | 55 | 30 | 13 | 14 | 40 |
Working Capital Days | 128 | 114 | 102 | 61 | 66 | -4 | 18 | 47 | 39 | 44 | 61 | 50 |
ROCE % | 12% | 10% | 9% | 12% | 11% | 12% | 16% | 25% | 22% | 23% |
Business Overview:[1]
PACL manufactures Active Pharma Ingredients for domestic and exports markets, they have a portfolio of 15 APIs and 10 Fine Chemicals. It produces the entire range of products in the Antacid Molecules segment